External Appeal Outcomes Data and Independent Review Organization Rulings

External appeal outcomes data shows independent reviewers overturning insurer denials at rates between 30% and 78%, depending on the case set and the year studied. The natural reading treats this as proof that the appeal system works: patients push back, neutral experts look again, and the correct outcome prevails. The data supports a harder conclusion. Every overturned denial is a case where a licensed clinician, with no stake in the outcome, looked at the same chart the insurer's own reviewer looked at and found the original decision could not stand. An Independent Review Organization is a neutral, privately accredited third party, usually under URAC accreditation required by federal rule, that checks whether a denial was clinically and contractually sound. Its reviewers must be board-certified in a relevant specialty, and the organization cannot have a financial or operational tie to the plan whose decision it is reviewing. When that reviewer overturns a denial, the ruling binds the plan: the insurer has to pay, and the decision is not a recommendation sent back for consideration. A denial reversed under those conditions was, in most cases, a denial that should not have been issued in the first place, not a close call that happened to tip once new facts came in. That distinction sets the frame for the rest of this piece: the IRO record reads less like a safety valve working as designed and more like a running tally of how often payers deny care that cannot hold up once someone without a financial interest looks at it.

How IRO review differs from internal appeals

The structural fact separating external review from everything that comes before it is who makes the call. First-level and second-level internal appeals are decided by the insurer itself, so the party with a financial interest in upholding the denial also holds the pen that could reverse it. That conflict is built into the design of internal appeal, not an occasional lapse in it. External review takes the insurer out of the room. Under 45 CFR § 147.136, the IRO assigned to a case must carry accreditation from URAC or a comparable nationally recognized accrediting body, and it answers to no one connected to the plan under review. Federal law requires non-grandfathered health plans to offer this external review route through accredited IROs, and that right stands in law whether or not an insurer makes it simple to use. It is formally a right that belongs to the patient, though a practice can file on a patient's behalf once the patient has assigned benefits to the practice or signed written authorization naming the practice as representative. Because the insurer has no hand in the outcome, an IRO reversal says something an internal appeal win cannot: a reviewer with nothing to gain and no relationship to the plan looked at the clinical record and concluded the denial was wrong. Washington State's Office of the Insurance Commissioner takes that logic a step further by publishing a searchable, publicly accessible database of IRO decisions, turning individual rulings into a running public record of how a given payer behaves over time.

Overturn patterns by payer and service category

New York state's record, drawn from 51,394 closed cases spanning May 31, 2019, through December 10, 2025, shows the problem is not spread evenly across the insurance market. IROs overturned more than half of denials in surgical services, dental and orthodontic procedures, and pharmacy or prescription drug claims within that same dataset. Substance abuse treatment and mental health denials ranked among the categories reversed most often, and denials tied to central nervous system or neuromuscular disorders, along with cancer-related denials, were also reversed at rates substantial enough to stand out. Broken down by named health plan, the New York analysis found wide variation from one insurer to the next: some plans saw a majority of their externally reviewed denials reversed, while others saw reversal rates closer to half. That spread matters because New York's data names the specific insurance companies behind each number, a level of disclosure researchers noted is unusually complete and may not exist in the same form in every state. Pennsylvania offers a parallel data point from its own state-run independent external review program, which has overturned roughly half of the eligible claims submitted since 2024, a pattern that has put health care benefits back in the hands of hundreds of Pennsylvania residents whose insurers had refused to cover them. None of these figures should be read as a national baseline; they describe New York and Pennsylvania specifically. This kind of data exists, and where it exists, it gives a practice a documented basis for treating a particular payer's denials as presumptively worth fighting the moment they land.

Why the appeal gap is the deeper problem

The overturn rate measures how often payers are wrong. A separate number measures how much that wrongness costs practices that never find out: the share of denied claims that are appealed at all is small, even though nearly half of the claims that do reach external review come back reversed. That gap, between how often a challenge would succeed and how rarely one is filed, is where the bulk of recoverable revenue disappears before anyone notices it is gone. Joseph Dov Bruch, PhD, the University of Chicago researcher behind the New York analysis, put the opportunity this way: "Consumers have a major opportunity to pursue these types of independent reviews after they exhaust the internal review. The opportunity sits in the data. It goes almost entirely unused in practice. Working through the full appeal sequence, first-level internal appeal, second-level internal appeal, and then external review, takes time, specific documentation, and procedural knowledge that most small practices cannot staff on a reliable basis. The cost of skipping that sequence is not abstract or deferred. A denied claim that would have been overturned, but is never appealed, is revenue the practice loses permanently once the filing deadline passes, with no later recovery available. Those deadlines run short: the federal baseline generally requires external review requests within four months of the final internal denial notice, and some states shorten that window further, so missing it ends the right. Seen from the payer's side, the incentive built by this gap is straightforward. An insurer that knows most denials will never be challenged bears the cost of reversal only on the small fraction of claims that make it all the way to appeal, which makes broad denial a rational strategy. The appeal gap is the predictable result of a system where not appealing is the easiest path available, and payers have little reason to change a process that works in their favor by default.

Which denials qualify for external review

Not every denial earns a seat in front of an IRO. External review becomes available when a denial turns on a question of medical judgment, such as medical necessity, an experimental treatment designation, off-label drug use, or a rescission of coverage, while pure coding and billing disputes may fall outside that right depending on the state. Before a case can reach external review, a practice generally has to exhaust internal appeals first, typically both the first-level and second-level reviews, unless the plan waives that requirement or the situation qualifies for expedited external review running alongside the internal process. Timing is unforgiving: the federal baseline sets a four-month window from the final internal denial notice, while California allows a longer window under its Independent Medical Review process, so a practice billing across several states needs to track the applicable deadline separately for each plan. Which process actually governs a given case comes down to how the plan is structured. A fully insured, state-regulated plan routes through the state external review process overseen by the state insurance commissioner, with a state-assigned or state-approved IRO handling the case. A self-funded ERISA plan, the kind common among large employers, instead follows the federal external review process overseen by the Department of Labor or HHS, with an accredited IRO assigned at random from a rotation of at least three organizations, and state external review protections apply only to fully insured plans. In states that lack a compliant external review law, cases fall to a federal fallback process administered by HHS. Medicare Advantage denials follow a separate track entirely, the Medicare grievance and appeals process run through CMS, with a Qualified Independent Contractor standing in for the URAC-accredited IRO used elsewhere. Grandfathered plans under the ACA carry no obligation to offer external review at all, so a practice should check the plan's Summary Plan Description before assuming the right applies. A practical tell appears on the explanation of benefits itself: an EOB that lists a third-party administrator separately from the insurance carrier is a common sign of a self-funded arrangement. Expedited external review, decided on a compressed timeline, applies when delay would seriously threaten the claimant's life or health, threaten the ability to regain maximum function, or involve a patient still admitted and not yet discharged from emergency care. For the independent and small practices billing mostly commercial and managed care plans, these track distinctions decide whether a denial even has a path forward, and knowing which one applies before the clock starts is what keeps that path open.

Building a winning external review submission

IRO physician reviewers decide cases on the clinical evidence and documentation in front of them, which puts the weight of the outcome on how well the submission makes its case. These reviewers hold board certification in a relevant specialty, and they weigh whether the denial matches current clinical standards by reading the insurer's own clinical policy bulletins against peer-reviewed medical literature. For a reversal, the IRO has to conclude the denial conflicted with the applicable standard of care, with evidence-based guidelines, or with the plan's own medical policies, and a submission needs to spell that conflict out for the reviewer. A complete submission includes several pieces working together: the final internal adverse benefit determination in writing, stating the specific reason for the denial; the full record of correspondence from the internal appeals that came before; medical records documenting the clinical basis for the service in question; a letter of medical necessity from the treating physician that answers the insurer's stated denial rationale point for point; and clinical evidence, drawn from peer-reviewed literature and specialty society guidelines, showing the service meets the accepted standard of care. The high overturn rates seen in home healthcare, behavioral health, and surgical services line up with categories where the clinical evidence for medical necessity is well established and insurer criteria get misapplied often, so documentation that cites current clinical guidelines directly undercuts the reasoning behind the original denial. A determination built on solid documentation and current evidence tends to survive review, while one that was rushed, applied inconsistently, or thinly supported is far more likely to be reversed, and a strong submission exposes that thinness directly. Authorization has to be settled before any of this starts: a practice filing on a patient's behalf needs assigned benefits or signed written authorization naming the practice as representative in place before the filing goes in. The real limit on pursuing external review at scale is what happens after a loss. If the IRO upholds the denial, the external review right is used up, leaving only state insurance department complaints for non-ERISA plans, direct negotiation, or federal court for self-funded ERISA plans, none of which most small practices can staff as a routine pipeline. Practices should put the strongest cases first, the ones where the clinical evidence is clearest and the denial rationale conflicts most with published criteria.

How payer-specific denial patterns should change upstream denial management

Treating each denial as a one-off loses the value that payer-specific overturn data builds over time. New York's figures are public record now, and state insurance department databases alongside IRO decision repositories, Washington State's searchable online database among them, give a practice documented grounds for treating a specific payer's denials as presumptively worth appealing. A payer that denies often but reverses quickly once an internal appeal is filed is signaling something specific: the original denial was administrative friction rather than a clinically defensible call, and tracking internal appeal overturn rates by payer turns that signal into an early warning system a practice can act on before a claim ever reaches external review. The service categories carrying the highest IRO overturn rates, home healthcare, behavioral health, and surgical services among them, are also the categories where spending more effort on documentation before a claim is submitted pays back most reliably. Prior authorization language, medical necessity letters, and clinical notes written at the time of care that map directly to published criteria cut the denial rate at the front end and make the appeal packet stronger at the back end, if a denial still comes through. The IRO overturn record, read payer by payer and category by category, functions as a map of where a practice's documentation effort returns the most revenue, and the practices that use it that way recover money the ones that treat every denial as final simply leave behind.